Article
Furmonertinib-based triplet therapy improves survival in EGFR-mutant NSCLC with leptomeningeal metastases: a large-scale multicenter retrospective study (FURMO-LM).
ESMO open - 1 Jun 2026
Chen H, Xu H, Yin Z, Li X, Lin G, Xin T, Yang H, Zhao Q, Cheng W, Zhang L, Li H, Xu W, Zheng H, Fan C, Wang F, Guo L, Wu Y, Wu Y, Yang S, Tang X, Zhu C, Fang S, Wang Q
Abstract excerpt
BACKGROUND: Leptomeningeal metastases (LM) in epidermal growth factor receptor mutant (EGFRm) non-small-cell lung cancer (NSCLC) represent a major therapeutic challenge. Despite the improved central nervous system penetration of third-generation EGFR tyrosine kinase inhibitors (TKIs), key uncertainties persist regarding the efficacy of combination regimens with antiangiogenic therapy and intrathecal chemotherapy...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.